ARTICLE | Strategy
Redux sets forth
June 17, 1996 7:00 AM UTC
Interneuron Pharmaceuticals Inc. graduated to the ranks of biotech companies with products for sale, launching its Redux dexfenfluramine for obesity with partner Wyeth-Ayerst Laboratories.
IPIC (Lexington, Mass.) will promote the drug through a 30-person sales force targeted at physician specialists, including endocrinologists, diabetologists, bariatricians, nutritionists and weight management specialists. ...